Scalable iPS-Derived Therapies with TreeFrog Therapeutics

1 July 2021
In this demo we are joined by TreeFrog Theraputics who share their innovative technology C-Stem for the  bio-production of cell therapy.

PLAY VIDEO ABOVE * TreeFrog Theraputics, the sponsor of this content would like to send you information about their products and services. If you do not wish to receive these emails, click here to opt out.

Kevin Alessandri, Co-Founder and Vice President describes the innovation behind C-Stem and its applications and advantages in bio-production for iPS-Cell therapies, in particular Parkinson’s disease. In the second part of this demo Maxime Feyeux, Co-Founder and Chief Scientific Officer answers questions regarding the transformative technology in this platform, discussing their business model, benefits for quality control, yield and reduced costs, future applications for the technology, and solving issues regarding scalability.

“We invented a new high-throughput technology which allows us to mass-produce iPS-based cell therapies, with flawless quality for cells and a new micro-graft format which both facilitates logistics and improves cell therapy efficacy.”


Phacilitate member? Watch this video and join the conversation via the network.

Not yet a member?
Join Today.